Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy children, 2 to 10 years of age who have up to date routine childhood vaccination, according to U.S. ACIP recommendations~Exclusion Criteria:~1. Unwilling or unable to give written informed assent or consent to participate in the study.~2. Perceived to be unreliable or unavailable for the duration of the study period.~3. Previous confirmed or suspected disease caused by N. meningitidis.~4. Previously immunized with a meningococcal vaccine (licensed or investigational).~5. Receipt of any investigational or non-registered product within 30 days prior to enrolment or who expect to receive an investigational drug or vaccine prior to the completion of the study.~6. Receipt or plan to receive any vaccines within 30 days before and after administration of each dose of the study vaccine.~   (certain exceptions influenza vaccines apply)~7. Significant acute infection within the 7 days prior to enrolment or body temperature of 38°C or greater within 3 days prior to enrolment.~8. Previous serious acute, chronic or progressive disease, epilepsy or any progressive neurological disease or history of Guillain-Barre syndrome.~9. History of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components~10. Impairment/alteration of immune function, either congenital or acquired or resulting from (for example):~    * receipt of immunosuppressive therapy,~   * receipt of immunostimulants,~   * receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives.~11. Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- 2 through 5 years (1 Vac) MenACWY-CRM 1 (Type: PLACEBO_COMPARATOR): Subjects 2 through 5 years received one vaccination of MenACWY-CRM
- 2 through 5 years (2 Vac) MenACWY-CRM 2 (Type: ACTIVE_COMPARATOR): Subjects 2 through 5 years received two vaccinations of MenACWY-CRM
- 6 through 10 years (1 Vac) MenACWY-CRM 3 (Type: PLACEBO_COMPARATOR): Subjects 6 through 10 years received one vaccination of MenACWY-CRM
- 6 through 10 years (2 Vac) MenACWY-CRM 4 (Type: ACTIVE_COMPARATOR): Subjects 6 through 10 years received two vaccinations of MenACWY-CRM

Based on this trial design, predict the completion outcome and termination type (if applicable).